Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL

Video

In Partnership With:

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma (MCL).

Historically, patients with relapsed/refractory MCL were treated with chemotherapy. Then, chemoimmunotherapy was utilized; however, it was not effective alone. High-dose therapy and transplant in addition to chemoimmunotherapy became the standard of care. Additionally, cytarabine became part of induction therapy, says Goy.

Patients with MCL tend to relapse often over the course of their disease, explains Goy. Additionally, these patients are often resistant to chemotherapy. As such, single-agent therapies have emerged demonstrating unprecedented response rates, as well as complete response rates, in the relapsed/refractory setting.

These novel agents include BTK inhibitors, lenalidomide (Revlimid), bortezomib (Velcade), and while not FDA approved, venetoclax (Venclexta), says Goy. Additionally, the mTOR inhibitor temsirolimus (Torisel) is approved in Europe for this patient population.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute